

1 **Title: MicroRNAs in adipocyte-derived extracellular vesicles in maternal and cord blood**
2 **are related to neonatal adiposity**

3
4 **Authors**

5 Pooja Kunte^{1*}, Matthew Barberio^{2*}, Pradeep Tiwari¹, Krishna Sukla¹, Brennan Harmon³,
6 Samuel Epstein³, Dattatray Bhat¹, Kayla Authelet³, Madeleine Goldberg³, Sudha Rao⁴,
7 Hemant Damle⁵, Robert J Freishtat³, Chittaranjan Yajnik¹ (corresponding)

8
9 *Co-first authors

10

11 **Affiliations**

12 ¹Diabetes Unit, KEM Hospital Research Centre, Pune, India

13 ²Department of Exercise and Nutrition Sciences, The Milken Institute School of Public
14 Health, George Washington University, Washington, D.C.

15 ³Center for Genetic Medicine Research, Children's National Hospital, Washington, D.C.

16 ⁴Genotypic Technology Pvt. Ltd., Bangalore, India

17 ⁵S K Navle hospital, Pune, India.

18

19

20 **Corresponding Author(s)**

21 csyajnik@gmail.com

22 rfreishtat@childrensnational.org

23

24

25 **Keywords:** Adipocyte-derived extracellular vesicles (ADsEV), microRNA, maternal and cord
26 blood, neonatal adiposity

1 **Abstract**

2 **Background:** Maternal body size, nutrition, and hyperglycemia contribute to neonatal body
3 size and composition. There is little information on maternal-fetal transmission of messages
4 which influence fetal growth. We analyzed adipocyte-derived small extracellular vesicular
5 (ADsEV) microRNAs in maternal and cord blood to explore their adipogenic potential.

6 **Methods:** We studied 127 mother-neonate pairs (51 lean and 76 adipose neonates, in 68
7 NGT and 59 GDM pregnancies). Adiposity refers to highest tertile (T3) of sum of skinfolds in
8 neonates of normal glucose tolerant (NGT) mothers, lean to lowest tertile (T1). ADsEV
9 miRNAs from maternal and cord blood samples were profiled on Agilent 8*60K microarray.
10 Differential expression (DE) of ADsEV miRNAs in adipose vs. lean neonates was studied
11 before and after adjustment for maternal gestational diabetes mellitus (GDM), adiposity,
12 and vitamin B12-folate status. **Results:** Multiple miRNAs were common in maternal and cord
13 blood and positively correlated. We identified 24 maternal and 5 cord blood miRNAs
14 differentially expressed ($p \leq 0.1$) in the adipose neonate group, and 19 and 26 respectively, in
15 the adjusted analyses. Even though DE miRNAs were different in maternal and cord blood,
16 they targeted similar adipogenic pathways (e.g., the forkhead box O (FOXO) family of
17 transcription factors, mitogen-activated protein kinase (MAPK) pathway, transforming
18 growth factor beta (TGF- β) pathway). Maternal GDM and adiposity were associated with
19 many DE ADsEV miRNAs.

20 **Conclusion:** Our results suggest that the DE ADsEV miRNAs in mothers of adipose neonates
21 are potential regulators of fetal adiposity. Further, the composition and functionality of
22 miRNAs may be influenced by maternal hyperglycemia, adiposity, and micronutrient status
23 during pregnancy.

24

25

26

27 **Abbreviations**

28 PMNS Pune Maternal Nutrition Study

29 PCS Pune Children Study

30 SSF Sum of skin folds

31 EV Extracellular vesicles

32 ADsEV Adipocyte derived small extracellular vesicles

33 GDM Gestational diabetes mellitus

34 NGT Normal glucose tolerant

35 FABP4 Fatty acid binding protein 4

36 DE miRNA Differentially expressed microRNA

37

1 Introduction

2 Women undergo many physiological adaptations during the gestational period to
3 promote healthy fetal growth¹. The developing fetus depends on transfer of nutrients from
4 the mother for the growth of its developing tissues and organs. Exposure of the fetus to
5 overnutrition (maternal hyperglycemia) or undernutrition (maternal macro- and micro-
6 nutrient deficiencies) during the intra-uterine development could create a ‘memory’ of
7 malnourishment which is proposed to “program” its risk for future adiposity, diabetes, and
8 cardiovascular diseases². This is the science of the Developmental Origins of Health and
9 Disease (DOHaD)³.

10 The Pune birth cohort studies (Pune Children’s Study (PCS) and Pune Maternal
11 Nutrition Study (PMNS)) provided significant insight into the fetal origins of elevated risk for
12 chronic disease⁴. The PMNS described the unique ‘thin-fat’ Indian baby which has lower
13 birth weight and lean mass, but comparable fat mass, to a European baby⁵. The thin-fat
14 Indian baby also has higher leptin and insulin but lower adiponectin concentrations in the
15 cord blood⁶. This neonatal ‘thin-fat’ phenotype is thought to originate in multi-generational
16 maternal undernutrition and is aggravated by maternal glycemia⁷. This phenotype continues
17 into postnatal life and contributes to the higher cardiometabolic risk in Indians compared to
18 Europeans⁸. In the Pune studies, low birth weight was associated with childhood insulin
19 resistance, and a maternal imbalance of low vitamin B12 and high folate status was
20 associated with high adiposity and insulin resistance in the offspring^{9,10}. Prediabetes in 18-
21 year-old offspring was predicted by poor linear growth *in utero* and by high normal glycemia
22 in the mother during pregnancy.

23 Understanding the molecular pathways leading to fetal adiposity are of interest to
24 the ‘primordial’ prevention of diabetes and other cardiometabolic diseases. Several
25 mechanisms, such as genetics, epigenetics, nutrients, and pro-inflammatory cytokines are
26 potential drivers of this intergenerational influence¹¹. Individually, they may explain only a
27 small proportion of the effect. For instance, genetic markers from genome wide association
28 studies account for less than 15% of the overall observed variance in the obesity
29 phenotypes^{12,13}. More recently small extracellular vesicles (sEV), sometimes called
30 exosomes, came into focus as potential mediators of intergenerational transfer due to their
31 ability to cross the placenta, the rise in sEV number in the maternal circulation during
32 pregnancy and their important role in cell-to-cell communication^{14,15}.

33 sEVs are endocytic vesicles with a lipid bilayer, are released by a wide range of cell
34 types and can transfer molecular cargo (e.g., proteins, nucleic acids, lipids) from the original
35 secreting cell to a recipient cell in a paracrine or endocrine fashion¹⁶. More specifically,
36 adipocyte-derived sEVs (ADsEV) have been shown to be a major source of circulating
37 microRNAs (miRNAs) which can regulate gene expression in distant tissues^{17,18}. We have
38 previously demonstrated that ADsEV miRNA contents are altered by obesity and normalized
39 following significant weight-loss (i.e., from bariatric surgery)^{19,20,21}. Further, ADsEVs from
40 individuals with obesity alter macrophage cholesterol efflux and gene expression *in vitro*²².
41 Given the important role of ADsEVs in obesity-related co-morbidities^{23,24}, our objective was

1 to explore ADsEV miRNAs as potential mediators of maternal-to-fetus communication and
2 transfer of intergenerational risk for adiposity. In this analysis, we examined differences in
3 miRNA profiles of ADsEVs isolated from maternal and cord blood plasma samples collected
4 at delivery in pregnancies with adipose and lean neonates, with the hypothesis that ADsEV
5 miRNAs will enhance adipogenic pathways.

6

7 **Methods**

8 **Cohort description:** The 'Intergenerational programming of diabetes in offspring of
9 women with gestational diabetes mellitus' (InDiaGDM) study investigated the impact of
10 maternal hyperglycemia on the risk of diabetes (diabetes + adiposity) in the offspring and
11 the modifying influence of vitamin B12 and folate status²⁵. Details of inclusion and exclusion
12 criteria are shown in the flowchart (Supplementary figure 1). All participating women signed
13 an informed consent, and the study was approved by the institutional ethics committee
14 (KEM EC no. 1404, SKNMC /Ethics/App/2014/265).

15 *Maternal and Neonatal Data.* Maternal socio-demographic data, medical and
16 obstetric information, and standard anthropometric measurements were taken at 28 weeks
17 gestation. A fasting oral glucose tolerance test (OGTT, 75-gram anhydrous glucose,
18 IADPSG²⁶) was performed at that time. Those diagnosed with gestational diabetes mellitus
19 (GDM) were appropriately advised. Delivery details (gestational age and type of delivery
20 (e.g., vaginal, cesarean)) were recorded. Detailed neonatal anthropometry was performed
21 within 24 hours of delivery (i.e., weight, length, head, and abdominal circumferences,
22 triceps, and subscapular skin folds).

23 **Biospecimen collection and determination of blood metabolites:** The following
24 measurements were made on maternal and cord blood: hemogram (complete blood count),
25 plasma glucose, insulin, total and HDL cholesterol, triglycerides, total vitamin B12, total
26 homocysteine and folate. Supplementary table 1 describes laboratory methods used for
27 these measurements.

28 **Definitions:** Neonatal adiposity (sex-stratified) was defined as highest tertile (T3) of
29 sum of skinfolds (SSF) of neonates born to normal glucose tolerant (NGT) mothers. T1 were
30 classified as lean. Maternal adiposity was defined from sub-scapular skin folds at 28 weeks'
31 gestation: above median (adipose) and below median (lean). GDM was diagnosed using
32 IADPSG criteria²⁶. Maternal vitamin B12 and folate status were classified as adequate if
33 above and inadequate if below the median concentration for the cohort.

34 **Sample processing randomization and blinding:** To avoid unintentional sampling
35 bias, the sample IDs were randomly ordered five times and then mother-neonate pairs were
36 grouped into batches of eight pairs (N=16). Laboratory staff were provided with a blinded
37 (i.e., no group information or metadata) processing order for samples.

38 **ADsEV isolation:** Maternal and cord blood plasma samples at delivery were treated
39 with 10 μ L [611U/mL] Thrombin (System Biosciences, Palo Alto, CA, USA) per 0.5mL plasma.
40 After a 10-minute incubation at room temperature, and centrifugation in a standard
41 microcentrifuge at 12,298 g for 10 minutes, the supernatant was removed and filtered

1 through a 0.2µm cellulose acetate syringe filter (VWR International, Radnor, PA, USA). Total
2 EVs were isolated from filtered plasma supernatants using ExoQuick exosome precipitation
3 solution (System Biosciences, Palo Alto, CA, USA) according to manufacturer's instructions.
4 ADsEVs were positively selected with a fatty acid-binding protein antibody (FABP4) (0.5
5 mg/mL; Mouse IgG monoclonal antibody, Abgent cat. No AM2235b, Inc., San Diego, CA,
6 USA) using a magnetic capture technique (EasySep™ "Do-It-Yourself" Positive Selection Kit II
7 - StemCell Technologies, Vancouver, BC, Canada). After positive selection, the ADsEVs were
8 resuspended in TRIzol™ Reagent (ThermoFisher Scientific, Waltham, MA, USA).

9 **MicroRNA isolation and assessment:** Exosomal RNA isolation was completed using
10 TRIzol reagent (ThermoFisher Scientific, Waltham, MA USA) according to manufacturer's
11 instructions. The quantity and quality of the RNA were assessed using a Nanodrop 2000
12 (ThermoFisher Scientific, Waltham, MA USA) and Bioanalyzer 2100 (Agilent Technologies,
13 Santa Clara, CA USA). Samples with OD260/OD280 ratio >1.5 and <2.2 were selected for
14 miRNA profiling. The miRNA labeling was performed using miRNA Complete Labeling and
15 Hyb Kit (Agilent Technologies, Santa Clara, CA, USA) with a sample input of 10uL of total
16 RNA. Samples were hybridized to Agilent Human miRNA Microarray, Release 21.0, 8x60K.
17 The microarray slides were scanned using an Agilent scanner (G2600D) and raw data
18 extracted using Agilent Feature Extraction software (Version 11.5.1.1).

19 **Statistical analyses:** Sample size and power calculations were done using "ssize"
20 package in R to measure a reliable fold change of 2.0 in miRNA expression in the adipose
21 group with respect to lean at a significance level of 0.05. A total of 120 individuals (~60 in
22 each group) would provide a power of 80%.

23 **Demographic characteristics:** Normally distributed data are presented as mean (SD)
24 and skewed data as median (25th and 75th percentiles). The significance of differences
25 between groups was tested by Student's t test (if normally distributed) or Mann-Whitney
26 test (if skewed).

27 **MicroRNA data:** Raw microRNA expression data was log2 transformed and
28 normalized using the 90th Percentile shift normalization method in GeneSpring GX (Version
29 14.5) software. MiRNAs that showed true signal in at least 10% of samples were selected for
30 further analysis. To check if the average expression of all ADsEV miRNAs was upregulated or
31 downregulated in the adipose group, mean z-scores of miRNA expression values were
32 calculated for all miRNAs from lean and adipose groups in maternal plasma and cord blood
33 and the distribution of z-scores between the groups were compared. We also investigated if
34 the ADsEV miRNA expression in maternal plasma samples correlated with those from cord
35 blood samples by applying a Spearman correlation test.

36 The central objective of the study was to compare differential expression of ADsEV
37 miRNAs in maternal plasma and cord blood of adipose (T3) and lean neonates (T1).
38 Differential expression of miRNAs between groups was calculated by Student's T test for
39 those normally distributed and by Mann-Whitney test for skewed. Fold changes were
40 calculated by formula: $FC = average(miRNA\ expression\ in\ adipose - median\ expression\ of\ miRNA\ in\ lean)$. This was done in 2 steps: 1. Without adjusting for confounding variables and

1 2. with adjusting for confounding variables (maternal GDM status, adiposity, and maternal
2 vitamin B12 and folate status for maternal samples, and additionally neonatal gender for
3 cord blood samples) by multiple linear regression analysis. We used a discovery significance
4 of $p \leq 0.1$ and a $FC \geq |1.2|$ and represented it as a volcano plot generated using ggplot2²⁵
5 package in R.

6 **Functional analyses:** Differentially expressed miRNAs with $p\text{-value} \leq 0.1$ were selected
7 for miRNA target gene and functional enrichment using Mienturnet²⁷ software
8 (<http://userver.bio.uniroma1.it/apps/mienturnet/>; March 2019). Target enrichment was
9 done using miRTarBase 8.0 and the functional enrichment was conducted by using the KEGG
10 database. This tool computationally maps the given list of miRNAs to their target
11 genes/proteins in their reference database (KEGG/miRTarBase) and fetches a list of target
12 genes that are computationally predicted and/or experimentally confirmed. Relevant
13 overrepresented classes of annotated genes with at least 1 miRNA-target interaction were
14 selected for functional enrichment and are studied. MicroRNAs targeting biological
15 pathways belonging to the following KEGG pathway categories are not shown because they
16 are of no direct interest in this analysis: cancer, bacterial/viral/parasitic infectious diseases,
17 excretory, immune and nervous system, immune and neurodegenerative diseases,
18 environmental adaptation, aging, substance abuse, and drug resistance. Pathways with FDR
19 $p\text{-value} \leq 0.05$ and related to adipogenesis, adipocyte differentiation and adipocyte signaling
20 were considered relevant from the KEGG pathway categories like cell growth and
21 development, signal transduction, metabolism, endocrine and cardiovascular health,
22 digestive systems and studied in detail. Fold changes of each DE miRNA in adipose group are
23 shown in a barplot. MiRNAs and their targeted genes are represented as a network plot,
24 generated using ggnet²⁸ package in R. A bubble plot of the functionally enriched miRNAs
25 was generated using ggplot2²⁹, where colour and size of each bubble stands for its FDR $p\text{-}$
26 value and the number of targeted genes, respectively. Adipogenesis related pathways
27 targeted by both maternal and cord blood DE miRNAs are highlighted using a Sankey
28 diagram generated using SankeyMatic³⁰ software.

29 **Differential expression of miRNAs in relation to maternal conditions**

30 **(hyperglycemia and adiposity during pregnancy):** To check the influence of maternal
31 conditions (i.e., hyperglycemia and adiposity during pregnancy) on ADsEV miRNA profile,
32 differential expression analysis was carried out in both maternal and cord blood ADsEV
33 miRNA profiles between following groups: 1. GDM and NGT (unadjusted and adjusted for
34 confounders: maternal adiposity, B12 and folate status) and 2. maternal adiposity (below
35 and above median) (unadjusted and adjusted for confounders: GDM, B12 and folate status).
36 The lists of DE miRNAs from the unadjusted and adjusted analyses were combined and
37 duplicates were removed. DE miRNAs from both analyses were subjected to functional
38 enrichment in Mienturnet and adipogenesis related pathways were screened. A Venn
39 diagram was made using jvenn³¹ software to compare the adipogenesis related microRNAs
40 from the three analyses: 1. Neonatal adiposity, 2. Maternal GDM, and 3. Maternal adiposity
41 in both maternal and cord blood.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

Results

The InDiaGDM study enrolled 413 women after applying inclusion and exclusion criteria. Of these, 330 women delivered at study centers. Two hundred and seventy-nine mother-neonate pairs had the necessary data and matching maternal plasma and cord blood samples. From these, guided by a power calculation, we randomly selected 127 mother-neonate pairs, including 51 lean and 76 adipose neonates, for ADsEV miRNA analyses (supplementary figure 1). There were no significant differences between the included (N=127) and excluded (N=152) mothers with respect to age, parity, weight, and BMI, or in their neonates with respect to gender, gestational age at the time of birth, and birth weight (supplementary table 2).

Characteristics of mothers and neonates: Mothers were a median (IQR) age of 27 (5) years old, 155 (7) cm tall, and had a BMI of 27.1 (6.6) kg/m² at 28 weeks' gestation. Of the 127 mothers, 68 were NGT and 59 were diagnosed with GDM. The mothers of adipose neonates had higher weight, BMI, SSF, and fasting glucose compared to mothers of lean neonates but similar levels of total and HDL cholesterol, triglycerides, vitamin B12, and folate (Table 1A). Adipose neonates had higher birth weight, length, SSF, and placental weight compared to lean neonates (Table 1B). Mothers of adipose neonates had higher prevalence of adiposity and GDM.

Differential expression of ADsEV miRNAs in maternal plasma and cord blood:

Of the 2549 miRNAs profiled in the Agilent 8*60k microarray, 742 miRNAs were detected in at least 1 sample. We chose miRNAs which were expressed in at least 10% of samples for further analysis (139 miRNAs in maternal and 144 in cord blood) (supplementary figure 2). We found that 118 miRNAs were common in maternal and cord blood. Of these, 74 (63%) were positively and significantly correlated ($p \leq 0.05$).

Comparison between the adipose and lean neonate groups identified 24 miRNAs differentially expressed in their mothers at $p \leq 0.1$ (13 with $FC \geq 1.25$ and 1 with $FC \leq -1.25$). After adjusting for maternal GDM, adiposity, vitamin B12, and folate status, 19 miRNAs remained differentially expressed between the groups (5 with $FC \geq 1.25$ and 1 with $FC \leq -1.25$) (Table 3A, Figure 1). In the cord blood, 5 ADsEV miRNAs were differentially expressed (3 with $FC \geq 1.25$ in adipose group). After adjusting for neonatal sex, maternal GDM, adiposity, vitamin B12, and folate status, the number of DE miRNAs in the cord blood increased to 26 (16 with $FC \geq 1.25$ and 3 with $FC \leq -1.25$ in adipose group) (Table 3B, Figure 1). After combining the lists of DE miRNAs in unadjusted and adjusted analyses and removing duplicates, 39 miRNAs in maternal and 29 miRNAs in cord blood were found to be differentially expressed in adipose group.

We investigated biological functional profile of the differentially expressed miRNAs. Target enrichment analysis (Mienturnet) highlighted 11 miRNAs to be upregulated in plasma

1 of mothers of adipose neonates compared to those of lean neonates (7 miRNAs in
2 unadjusted analysis: hsa-miR-1202, hsa-miR-1234-3p, hsa-miR-212-3p, hsa-miR-33b-3p, hsa-
3 miR-451a, hsa-miR-4271 and hsa-miR-5787; and 4 miRNAs in the adjusted analyses: hsa-
4 miR-211-3p, hsa-miR-212-3p, hsa-miR-483-3p, hsa-miR-4649-3p). The fold changes are
5 shown in Table 2 and Figures 2 and 3. Further screening based on KEGG ontology revealed 4
6 miRNAs to be targeting genes involved in pathways related to adipogenesis.

7 Target enrichment analysis in the cord blood highlighted 11 miRNAs (4 miRNAs in
8 unadjusted analysis, two upregulated: hsa-miR-483-5p, hsa-miR-3162-3p, two
9 downregulated: hsa-miR-15a-3p, hsa-miR-342-3p; and 7 miRNAs in the adjusted analysis
10 five upregulated: hsa-miR-1225-5p, hsa-miR-181b-5p, hsa-miR-204-5p, hsa-miR-3162-3p,
11 hsa-miR-519e-3p; and two downregulated: hsa-miR-92a-3p, hsa-miR-212-3p). Based on
12 KEGG ontology, 9 miRNAs of these were targeting genes involved in pathways related to
13 adipogenesis.

14 We used a Sankey diagram (figure 4) to depict the inter-relationships between
15 differentially expressed miRNAs in maternal and cord blood (of adipose neonates) and their
16 targeted adipogenic pathways. The highlighted pathways included adipocytokine signaling,
17 FoxO signaling, MAPK signaling, Hedgehog signaling, Wnt signaling, insulin signaling, AGE-
18 RAGE signaling, cAMP signaling, JAK-STAT signaling, Ras signaling, and TGF-beta signaling.

19 We compared differential expression of ADsEV miRNAs in plasma of adipose vs. non-
20 adipose and in GDM vs NGT mothers and in the cord blood of their neonates. We found 127
21 DE ADsEV miRNAs in adipose and 106 in GDM mothers, and 57 and 82 in the cord blood,
22 respectively. Of these, 25 miRNAs in the adipose and 19 in the GDM mothers were related
23 to adipogenesis, the corresponding number in the cord blood was 16 and 17 respectively.

24 Figure 5 shows that 28 miRNAs were common in maternal blood amongst adipose
25 mothers, GDM mothers and adipose neonates and 3 of them were related to adipogenesis:
26 hsa-miR-451a, hsa-miR-212-3p, hsa-miR-1234-3p and 13 miRNAs were common in cord
27 blood of which only 1 hsa-miR-204-5p was related to adipogenesis based on KEGG ontology.

28
29
30

31 Discussion

32 There are few reports of ADsEV miRNAs in mother-neonate pairs. We investigated
33 the association between ADsEV miRNAs in maternal and cord blood with neonatal body
34 composition to understand their potential influence on neonatal adiposity. A large majority
35 (~85%) of ADsEV miRNAs in maternal and cord blood were common, and two-thirds of these
36 were positively correlated suggesting a crosstalk between maternal adipose and neonatal
37 tissue. Maternal adiposity and hyperglycemia, two major determinants of neonatal
38 adiposity were both associated with differential expression of a relatively large number of
39 ADsEV miRNAs in maternal and fetal circulation, a fifth of these were functionally related to
40 adipogenesis. In the maternal circuit, these may represent adipose tissue dysfunction (i.e.,
41 adiposopathy) and have the potential to influence fetal growth and body composition.

1 Our primary analysis was to investigate maternal and cord blood miRNAs associated
2 with neonatal adiposity. The tables 2 and 3 and the Sankey figure (Figure 4) show that the
3 differentially expressed miRNAs were different in maternal and cord blood (except hsa-miR-
4 212-3p which was common). Interestingly, they targeted the genes well-known to influence
5 cellular signaling pathways related to adipogenesis. (FoxO, MAPK, Insulin, AGE-RAGE
6 signaling, etc.) (figure 4). Literature survey revealed experimental evidence of the
7 involvement of some of these miRNAs in aspects of adipogenesis. Maternal miRNAs hsa-
8 miR-483-3p (FC= 3.99 in adipose group) and hsa-miR-212-3p (FC=0.282 in adipose group)
9 have been associated with lipid accumulation and adipocyte differentiation in low-birth-
10 weight adult humans³², and with increased subcutaneous adipose tissue inflammation³³,
11 respectively. In an earlier study we found that hsa-miR-212-3p is associated with increased
12 risk of glucose intolerance in young adult PMNS female participants³⁴. Fetal miRNAs hsa-
13 miR-204-3p (FC=9.87 in adipose group) and hsa-miR-342-3p (FC=-0.098) have been shown
14 to promote adipogenic differentiation of mesenchymal stem cells^{35,36} and hsa-miR-15a (FC=
15 -0.912) to regulate intramuscular adipogenesis³⁷. Given that neonates have a substantial
16 proportion of brown adipose tissue (BAT) and that Indians have lower BAT compared to
17 Europeans, we investigated if any of these DE miRNAs have originated in the BAT.
18 Intriguingly, hsa-miR-92a-3p (FC= -0.36) and hsa-miR-181 (FC= 0.71 in adipose group) which
19 are associated with brown fat activity^{38,39} are found to be differentially expressed only in
20 cord blood, reflecting active brown fat activity in neonates. Together our results show a role
21 for DE miRNAs in influencing maternal adipocyte function and fetal adipogenesis. We
22 consider that our results provide an insight in the possible role of ADsEV miRNAs (maternal
23 and fetal) in influencing neonatal adiposity and raise the possibility that they could act as
24 maternal-fetal signaling system.

25 Growth and development of the fetus depends on coordinated timely expression of
26 genes which is epigenetically regulated⁴⁰. Body composition of the fetus is probably
27 determined from very early pregnancy when the fate of the three germ layers is decided
28 (gastrulation). Adipogenesis involves 'commitment' of mesenchymal stem cells to develop
29 as pre-adipocytes which subsequently differentiate into adipocytes⁴¹. Several specific genes
30 regulate these steps and the expression of these genes in turn is regulated by DNA
31 methylation, histone modifications and specific miRNAs^{42,43,44}. The role of DNA methylation
32 in adipogenesis has been studied^{45,46} but there is little information on the other epigenetic
33 mechanisms (i.e., miRNA regulation). Light microscopic studies in human abortuses
34 demonstrate that pre-adipocyte to adipocyte differentiation happens between 19 to 23
35 weeks, after which period only adipocyte size increases by lipid accumulation⁷. Two major
36 maternal determinants of these processes are maternal nutrition (both macro- and micro-
37 nutrients) and her metabolism (diabetes and associated metabolic abnormalities)⁴⁷. There is
38 only scant information on how these two stimuli influence molecular adipogenesis in the
39 baby, though insulin secretion by fetal pancreas is an important mechanism (Abigail
40 Fouden). Maternal hyperglycemia promotes fetal hyperinsulinemia (Pedersen's
41 hypothesis)⁴⁸, lipids and amino acids probably work similarly (Freinkel's fuel mediated

1 teratogenesis)⁴⁹. In our novel approach we have investigated the possible involvement of
2 maternal ADsEV miRNAs in influencing fetal adiposity and suggest that DE ADsEV miRNAs in
3 both the maternal and neonatal circulation could influence neonatal adiposity through
4 regulating various cellular signaling pathways which are well-known to be involved in
5 different aspects of adipogenesis. Though our investigation does not allow us to confirm
6 maternal origin of ADsEVs in fetal circulation, many studies have demonstrated maternal-
7 fetal transfer of EVs.

8 Our study is perhaps the first of its kind to investigate association of maternal and
9 fetal ADsEV miRNAs and neonatal adiposity. This is a novel approach to fetal growth and
10 development and may provide useful leads into possible molecular mechanisms of maternal
11 fetal communication. An additional strength is a reasonable number of mother-baby dyads
12 in each group in a population which is characterized by adipose newborns (thin-fat Indian
13 babies). One of the limitations is that the maternal ADsEV miRNAs were measured only at
14 the time of delivery and thus after neonatal adiposity is established; we will investigate
15 maternal ADsEVs in early pregnancy to expand our findings. It is also true that the current
16 design is not provide conclusive proof of transfer of maternal ADsEVs to fetal circulation,
17 and therefore our results are to be considered hypothesis generating and in need of further
18 proof by experiments like HLA typing and matching of ADsEVs to track their origin.
19 Moreover, as Indians are reported to have lower BAT compared to Europeans and it will be
20 interesting to pursue adiposity trajectory and metabolic outcomes in these children in
21 relation to cord blood ADsEVs. External validity of our findings will come only from
22 additional studies in other populations.

23 In summary, we demonstrate differential expression of ADsEV miRNAs both in
24 maternal and neonatal circulation in pregnancies with adipose neonates. These miRNAs
25 targeted different aspects of adipose tissue function and adipogenesis, supporting a
26 possible role in fetal adipogenesis. Studies in other populations and in early pregnancy will
27 improve our understanding of maternal-fetal communication which influences fetal body
28 composition.

29

30 **Data availability**

31 The demographic, phenotypic and raw microarray data is available with the authors and can
32 be made available for a reasonable request following institutional clearances.

33

34 **Funding**

35 The work was supported by InDiaGDM grant of the Department of Biotechnology, New Delhi,
36 India (BT/IN/Denmark/02/CSY/2014) and National Institute of Health (NIH), the U.S
37 government (R21HD094127-01).

38

39 **Acknowledgement**

40 The authors thank Deepa Raut, Neelam Memane, Sayali Wadke and Rajashree Kamat for their
41 help in processing cord blood samples and laboratory assays. Madhura Deshmukh for help in
42 study coordination. Mrs. Pallavi Yajnik and Rasika Ladkat for administrative help. Dr. Leelavati
43 Narlikar for her guidance in data analysis. Dr. Satyajit Rath for his advice in writing t

1 discussion. We also thank the co-investigators of the InDiaGDM study Dr. Giriraj Chandak,
2 Kalyanaraman Kumaran, Dr. Gundu Rao for their valuable contribution in conducting the
3 InDiaGDM study.

4

5 **Author contributions**

6 CSY designed the InDiaGDM study. CSY and HD contributed to managing the clinical cohort.
7 DB, RKK, BH, ES, MB contributed to exosome extraction and protocol standardization. SR
8 contributed to microRNA data generation. PSK, PT, MB, RKK, KA, MG contributed to the
9 data analysis. PSK, MB, CSY, RF contributed to the manuscript writing. CSY and RF
10 contributed to discussion and interpretation of the results. All authors read and approved
11 the manuscript.

12

13

1 **References**

- 2 1. Williams, R. Hardin., & Larsen, P. Reed. (2003). Chapter 20. Endocrine Changes in
3 Pregnancy, Williams textbook of endocrinology. Saunders.
- 4 2. Hales, C. N., & Barker, D. J. P. (2013). Type 2 (non-insulin-dependent) diabetes
5 mellitus: the thrifty phenotype hypothesis. 1992. *International Journal of*
6 *Epidemiology*, 42(5), 1215–1222. doi: 10.1093/ije/dyt133
- 7 3. Yajnik, C. S., & Deshmukh, U. S. (2008). Maternal nutrition, intrauterine programming
8 and consequential risks in the offspring. *Reviews in Endocrine & Metabolic Disorders*,
9 9(3), 203–211. doi: 10.1007/s11154-008-9087-z
- 10 4. Katre P, & Yajnik C. (2015). Pune Experience.
- 11 5. Yajnik, C S, Fall, C. H. D., Coyaji, K. J., Hirve, S. S., Rao, S., Barker, D. J. P., Joglekar, C., &
12 Kellingray, S. (2003). Neonatal anthropometry: the thin-fat Indian baby. The Pune
13 Maternal Nutrition Study. *International Journal of Obesity and Related Metabolic*
14 *Disorders : Journal of the International Association for the Study of Obesity*, 27(2),
15 173–180. doi: 10.1038/sj.ijo.802219
- 16 6. Yajnik, C S, Lubree, H. G., Rege, S. S., Naik, S. S., Deshpande, J. A., Deshpande, S. S.,
17 Joglekar, C. v, & Yudkin, J. S. (2002). Adiposity and hyperinsulinemia in Indians are
18 present at birth. *The Journal of Clinical Endocrinology and Metabolism*, 87(12), 5575–
19 5580. doi: 10.1210/jc.2002-020434
- 20 7. Yajnik, Chittaranjan S, & Yajnik, P. C. (2020). Fetal adiposity epidemic in the modern
21 world: a thrifty phenotype aggravated by maternal obesity and diabetes. *AJCN*. doi:
22 10.1093/ajcn/nqaa122
- 23 8. D’Angelo, S., Yajnik, C. S., Kumaran, K., Joglekar, C., Lubree, H., Crozier, S. R., Godfrey,
24 K. M., Robinson, S. M., Fall, C. H. D., Inskip, H. M., & SWS Study Group and the PMNS
25 Study Group. (2015). Body size and body composition: a comparison of children in
26 India and the UK through infancy and early childhood. *Journal of Epidemiology and*
27 *Community Health*, 69(12), 1147–1153. doi: 10.1136/jech-2014-204998
- 28 9. Bavdekar, A., Yajnik, C. S., Fall, C. H., Bapat, S., Pandit, A. N., Deshpande, V., Bhave, S.,
29 Kellingray, S. D., & Joglekar, C. (1999). Insulin resistance syndrome in 8-year-old Indian
30 children: small at birth, big at 8 years, or both? *Diabetes*, 48(12), 2422–2429. doi:
31 10.2337/diabetes.48.12.2422
- 32 10. Yajnik, C S, Deshpande, S. S., Jackson, A. A., Refsum, H., Rao, S., Fisher, D. J., Bhat, D.
33 S., Naik, S. S., Coyaji, K. J., Joglekar, C. v, Joshi, N., Lubree, H. G., Deshpande, V. U.,
34 Rege, S. S., & Fall, C. H. D. (2008). Vitamin B12 and folate concentrations during
35 pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study.
36 *Diabetologia*, 51(1), 29–38. doi: 10.1007/s00125-007-0793-y
- 37 11. Kaspar, D., Hastreiter, S., Irmeler, M. et al. Nutrition and its role in epigenetic
38 inheritance of obesity and diabetes across generations. *Mamm Genome* 31, 119–133
39 (2020). <https://doi.org/10.1007/s00335-020-09839-z>

- 1 12. Reichetzeder, C. (2021). Overweight and obesity in pregnancy: their impact on
2 epigenetics. *European Journal of Clinical Nutrition*, 75, 1710–1722. doi:
3 10.1038/s41430-021-00905-6
- 4 13. Wang, K., Li, W.-D., Zhang, C. K., Wang, Z., Glessner, J. T., Grant, S. F. A., Zhao, H.,
5 Hakonarson, H., & Price, R. A. (2011). A genome-wide association study on obesity and
6 obesity-related traits. *PloS One*, 6(4), e18939. doi: 10.1371/journal.pone.0018939
- 7 14. Czernek, L., & Döchler, M. (2020). Exosomes as Messengers Between Mother and
8 Fetus in Pregnancy. *International Journal of Molecular Sciences*, 21(12). doi:
9 10.3390/ijms21124264
- 10 15. Sarker, S., Scholz-Romero, K., Perez, A., Illanes, S. E., Mitchell, M. D., Rice, G. E., &
11 Salomon, C. (2014). Placenta-derived exosomes continuously increase in maternal
12 circulation over the first trimester of pregnancy. *Journal of Translational Medicine*, 12,
13 204. doi: 10.1186/1479-5876-12-204
- 14 16. Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina,
15 R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G. K., Ayre, D. C., Bach, J.-M.,
16 Bachurski, D., Baharvand, H., Balaj, L., Baldacchino, S., Bauer, N. N., Baxter, A. A.,
17 Bebawy, M., ... Zuba-Surma, E. K. (2018). Minimal information for studies of
18 extracellular vesicles 2018 (MISEV2018): a position statement of the International
19 Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *Journal of*
20 *Extracellular Vesicles*, 7(1), 1535750. doi: 10.1080/20013078.2018.1535750
- 21 17. Thomou T, Mori MA, Dreyfuss JM, et al. Adipose-derived circulating miRNAs regulate
22 gene expression in other tissues. *Nature* 2017;542:450-5.
- 23 18. Boon RA, Vickers KC. Intercellular transport of microRNAs. *Arterioscler Thromb Vasc*
24 *Biol* 2013;33:186-92.
- 25 19. Ferrante SC, Nadler EP, Pillai DK, et al. Adipocyte-derived exosomal miRNAs: a novel
26 mechanism for obesity-related disease. *Pediatric research* 2015;77:447-54.
- 27 20. Hubal MJ, Nadler EP, Ferrante SC, et al. Circulating adipocyte-derived exosomal
28 MicroRNAs associated with decreased insulin resistance after gastric bypass. *Obesity*
29 (Silver Spring) 2017;25:102-10.
- 30 21. Hromadnikova I, Kotlabova K, Dvorakova L, Krofta L, Sirc J. Substantially Altered
31 Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated
32 microRNAs in Children Descending from Pregnancy Complicated by Gestational
33 Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular
34 Risk. *Cells* 2020;9.
- 35 22. Xie Z, Wang X, Liu X, et al. Adipose-Derived Exosomes Exert Proatherogenic Effects by
36 Regulating Macrophage Foam Cell Formation and Polarization. *J Am Heart Assoc*
37 2018;7.
- 38 23. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity
39 is associated with macrophage accumulation in adipose tissue. *J Clin Invest*
40 2003;112:1796-808.

- 1 24. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the
2 development of obesity-related insulin resistance. *J Clin Invest* 2003;112:1821-30.
- 3 25. Wagle S, Phatak S, Bhat D et al. Adiposity and Glucose Intolerance in Offspring of
4 Diabetic Mothers in India. medRxiv 2021.05.17.21257222; doi:
5 <https://doi.org/10.1101/2021.05.17.21257222>
- 6 26. International Association of Diabetes and Pregnancy Study Groups Recommendations
7 on the Diagnosis and Classification of Glucose intolerance in Pregnancy. *Diabetes Care*.
8 2010;33(3):676-682.
- 9 27. Licursi, V., Conte, F., Fison, G. et al. MIENTURNET: an interactive web tool for
10 microRNA-target enrichment and network-based analysis. *BMC Bioinformatics* 20,
11 545 (2019). <https://doi.org/10.1186/s12859-019-3105-x>
- 12 28. Butts C (2015). `_network: Classes for Relational Data_`. The Statnet Project
13 (<URL:<http://www.statnet.org>>). R package version 1.13.0.1, <URL:[https://CRAN.R-](https://CRAN.R-project.org/package=network)
14 [project.org/package=network](https://CRAN.R-project.org/package=network)>.
- 15 29. Wickham H (2016). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New
16 York. ISBN 978-3-319-24277-4, <https://ggplot2.tidyverse.org>.
- 17 30. SankeyMATIC: A Sankey diagram builder for everyone (<https://sankeymatic.com/>)
- 18 31. Philippe Bardou, Jérôme Mariette, Frédéric Escudié, Christophe Djemiel and
19 Christophe Klopp. jvenn: an interactive Venn diagram viewer. *BMC Bioinformatics*
20 2014, 15:293 doi:10.1186/1471-2105-15-293
- 21 32. Ferland-McCollough, D., Fernandez-Twinn, D. S., Cannell, I. G., David, H., Warner, M.,
22 Vaag, A. A., Bork-Jensen, J., Brøns, C., Gant, T. W., Willis, A. E., Siddle, K., Bushell, M.,
23 & Ozanne, S. E. (2012). Programming of adipose tissue miR-483-3p and GDF-3
24 expression by maternal diet in type 2 diabetes. *Cell Death and Differentiation*, 19(6),
25 1003–1012. doi: 10.1038/cdd.2011.183
- 26 33. Nardelli, C., Iaffaldano, L., Pilone, V., Labruna, G., Ferrigno, M., Carlomagno, N.,
27 Dodaro, C. A., Forestieri, P., Buono, P., Salvatore, F., & Sacchetti, L. (2017). Changes in
28 the MicroRNA Profile Observed in the Subcutaneous Adipose Tissue of Obese Patients
29 after Laparoscopic Adjustable Gastric Banding. *Journal of Obesity*, 2017, 6754734. doi:
30 10.1155/2017/6754734
- 31 34. Joglekar, M. v, Kunte, P. S., Wong, W. K. M., Bhat, D. S., Satoor, S. N., Patil, R. R.,
32 Karandikar, M. S., Fall, C. H. D., Yajnik, C. S., & Hardikar, A. A. (2022). Circulating
33 microRNAs from early childhood and adolescence are associated with pre-diabetes at
34 18 years of age in women from the PMNS cohort. *Journal of Developmental Origins of*
35 *Health and Disease*, 1–6. doi: 10.1017/S2040174422000137
- 36 35. Wang, L., Xu, L., Xu, M., Liu, G., Xing, J., Sun, C., & Ding, H. (2015). Obesity-Associated
37 MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2
38 and Releasing C/EBP α from CtBP2 Binding. *Cellular Physiology and Biochemistry :*
39 *International Journal of Experimental Cellular Physiology, Biochemistry, and*
40 *Pharmacology*, 35(6), 2285–2298. doi: 10.1159/000374032

- 1 36. He, H., Chen, K., Wang, F., Zhao, L., Wan, X., Wang, L., & Mo, Z. (2015). miR-204-5p
2 promotes the adipogenic differentiation of human adipose-derived mesenchymal
3 stem cells by modulating DVL3 expression and suppressing Wnt/ β -catenin signaling.
4 *International Journal of Molecular Medicine*, 35(6), 1587–1595. doi:
5 10.3892/ijmm.2015.2160
- 6 37. Li, G., Fu, S., Chen, Y., Jin, W., Zhai, B., Li, Y., Sun, G., Han, R., Wang, Y., Tian, Y., Li, H.,
7 & Kang, X. (2019). MicroRNA-15a Regulates the Differentiation of Intramuscular
8 Preadipocytes by Targeting ACAA1, ACOX1 and SCP2 in Chickens. *International Journal*
9 *of Molecular Sciences*, 20(16). doi: 10.3390/ijms20164063
- 10 38. Chen, Y., Buyel, J. J., Hanssen, M. J. W., Siegel, F., Pan, R., Naumann, J., Schell, M., van
11 der Lans, A., Schlein, C., Froehlich, H., Heeren, J., Virtanen, K. A., van Marken
12 Lichtenbelt, W., & Pfeifer, A. (2016). Exosomal microRNA miR-92a concentration in
13 serum reflects human brown fat activity. *Nature Communications*, 7, 11420. doi:
14 10.1038/ncomms11420
- 15 39. Machado SA, Pasquarelli-do-Nascimento G, da Silva DS, Farias GR, de Oliveira Santos
16 I, Baptista LB, Magalhães KG. Browning of the white adipose tissue regulation: new
17 insights into nutritional and metabolic relevance in health and diseases. *Nutr Metab*
18 (Lond). 2022 Sep 6;19(1):61. doi: 10.1186/s12986-022-00694-0. PMID: 36068578;
19 PMCID: PMC9446768.
- 20 40. Zhu, Z., Cao, F., & Li, X. (2019). Epigenetic Programming and Fetal Metabolic
21 Programming. *Frontiers in Endocrinology*, 10, 764. doi: 10.3389/fendo.2019.00764
- 22 41. Sebo, Z. L., Jeffery, E., Holtrup, B., & Rodeheffer, M. S. (2018). A mesodermal fate map
23 for adipose tissue. *Development (Cambridge, England)*, 145(17).
24 doi:10.1242/dev.166801
- 25 42. Ambele, M. A., Dhanraj, P., Giles, R., & Pepper, M. S. (2020). Adipogenesis: A Complex
26 Interplay of Multiple Molecular Determinants and Pathways. *International Journal of*
27 *Molecular Sciences*, 21(12). doi: 10.3390/ijms21124283
- 28 43. Ghaben, A. L., & Scherer, P. E. (2019). Adipogenesis and metabolic health. *Nature*
29 *Reviews. Molecular Cell Biology*, 20(4), 242–258. doi: 10.1038/s41580-018-0093-z
- 30 44. Samblas, M., Milagro, F. I., & Martínez, A. (2019). DNA methylation markers in obesity,
31 metabolic syndrome, and weight loss. *Epigenetics*, 14(5), 421–444. doi:
32 10.1080/15592294.2019.1595297
- 33 45. Crocker, K. C., Domingo-Relloso, A., Haack, K., Fretts, A. M., Tang, W.-Y., Herreros, M.,
34 Tellez-Plaza, M., Daniele Fallin, M., Cole, S. A., & Navas-Acien, A. (2020). DNA
35 methylation and adiposity phenotypes: an epigenome-wide association study among
36 adults in the Strong Heart Study. *International Journal of Obesity (2005)*, 44(11), 2313–
37 2322. doi: 10.1038/s41366-020-0646-z
- 38 46. Rosen, E. D., & MacDougald, O. A. (2006). Adipocyte differentiation from the inside
39 out. *Nature Reviews. Molecular Cell Biology*, 7(12), 885–896. doi: 10.1038/nrm2066

- 1 47. Yajnik, C. S. (2014). Transmission of obesity-adiposity and related disorders from the
2 mother to the baby. *Annals of Nutrition & Metabolism*, 64 Suppl 1, 8–17. doi:
3 10.1159/000362608
- 4 48. Pedersen J. Diabetes and pregnancy: Blood sugar of newborn infants (Ph.D. Thesis)
5 Danish Science Press; Copenhagen: 1952. p. 230.
- 6 49. Freinkel N. Banting Lecture 1980. Of pregnancy and progeny. *Diabetes* 29(12): 1023-
7 1035.
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28

1 **Table 1. Comparison of demographic characteristics between mothers of lean vs. mothers**
2 **of adipose neonates, and lean vs. adipose neonates**

	n	Mothers of Lean neonates	n	Mothers of Adipose neonates	p-value
Age (yr)	50	26.9 (4.3)	75	27.9 (4.6)	0.234
Pre-pregnancy weight (kg)	47	54.0 (47.0, 62.0)	76	59.0 (50.8, 65.2)	0.076
Height (cm)	51	154.8 (6.0)	75	154.9 (5.4)	0.868
Weight (kg)	51	61.3 (54.7, 68.2)	75	66.7 (59.0, 75.6)	0.006
BMI (kg/m ²)	51	25.0 (23.2, 27.6)	75	28.1 (25.4, 30.8)	0.003
Subscapular skin folds (mm)	50	34.7 (28.3, 41.3)	75	40.0 (29.0, 48.0)	0.058
% Adipose mothers		19/51 (37.2%)		42/76 (55.20%)	0.070
Fasting glucose (mg/dL)	51	80.0 (73.5, 87.0)	71	83.0 (78.0, 92.0)	0.034
% GDM mothers		17/51 (33.33%)		42/76 (55.26%)	0.024
Fasting Insulin (IU/L)	49	8.8 (5.9, 12.1)	68	9.7 (7.0, 14.5)	0.172
iHoma Sensitivity	49	106.6 (77.9, 152.3)	68	96.8 (63.3, 130.9)	0.133
iHoma Beta	49	125.7 (95.6, 144.6)	68	116.8 (93.7, 150.9)	0.932
iDI (*10 ³)	49	12.6 (10.4, 15.7)	68	11.2 (8.3, 14.7)	0.041
Vitamin B12 (pmol/L)	51	223 (171, 279)	73	206 (158, 280)	0.539
Folate (nmol/L)	51	57.4 (35.2, 70.7)	75	53.9 (25.3, 71.6)	0.612
Homocysteine (μmol/L)	29	6.8 (4.5, 7.5)	40	6.8 (5.8, 7.9)	0.496
Cholesterol (mg/dL)	49	203.7 (40.2)	71	193. (41.7)	0.179
Triglycerides (mg/dL)	49	144.0 (115.0, 213.0)	71	144.0 (115.5, 195.5)	0.949
HDL (mg/dL)	49	59.5 (14.1)	71	55.8 (13.3)	0.143
Neonatal characteristics (male=61, female=66)					
Gestational age (days)	51	229 (219, 244)	75	224 (211, 246)	0.607
Birth weight (g)	51	2519.3 (365.7)	76	3037.4 (369.1)	< 0.01
Birth Length (cm)	51	48.0 (46.2, 48.8)	76	49.0 (47.9, 49.7)	< 0.01
Sub-scapular skin fold (mm)	51	3.3 (3.0, 3.6)	76	5.2 (4.7, 5.8)	< 0.01
Placental weight (g)	51	360 (320, 405)	75	448 (390, 536)	< 0.01
Cord blood: Glucose (mg%)	51	60.0 (45.5, 80.5)	76	67.5 (52.8, 86.0)	0.379
Cord blood: Insulin (IU/L)	51	5.2 (2.2, 7.4)	76	6.9 (3.9, 12.5)	0.012
Cord blood: Vit B12 (pmol/L)	51	329 (199, 607)	76	288 (187, 475)	0.221
Cord blood: Folate (nmol/L)	51	57.4 (38.5, 69.2)	75	53.6 (33.5, 65.2)	0.214
Cord blood: Homocysteine (μmol/L)	41	6.4 (5.6, 8.9)	63	6.0 (5.0, 8.3)	0.133
Cord blood: Cholesterol (mg/dL)	51	53.0 (41.5, 62.5)	76	51.5 (40.0, 63.0)	0.996
Cord blood: Triglycerides (mg/dL)	51	46.0 (31.5, 52.5)	76	33.0 (25.0, 45.0)	< 0.01
Cord blood: HDL (mg/dL)	51	20 (15, 26)	76	21 (15, 27)	0.465

3 **Note:** Data are presented as mean (SD) and p-values are calculated by Student's T-test if
4 data is normally distributed, whereas median (25th, 75th centile) and p-values calculated by
5 Mann-Whitney are presented if data is not normally distributed.
6 Numbers and percentage are shown for % adipose mothers and % GDM mothers, p-values
7 are calculated by Chi-squared test.
8 BMI: Body Mass Index; HOMA: Homeostatic Model Assessment models, DI: Disposition
9 index. SD: Standard deviation.

1 **Table 2A. Lists of differentially expressed ADsEV miRNAs in mothers of adipose Vs lean**
2 **neonates**

Maternal miRNA (unadjusted)			Maternal miRNA (adjusted)		
miRNA	P-value	Fold change	miRNA	P-value	Fold change
hsa-miR-1202	0.061	1.544	hsa-miR-211-3p	0.073	1.55
hsa-miR-1234-3p	0.088	0.214	hsa-miR-212-3p	0.06	0.28
hsa-miR-1260a	0.057	1.784	hsa-miR-2276-3p	0.015	0.65
hsa-miR-212-3p	0.033	0.282	hsa-miR-3620-5p	0.053	-0.22
hsa-miR-3162-5p	0.082	0.911	hsa-miR-3928-5p	0.008	-0.09
hsa-miR-33b-3p	0.053	1.13	hsa-miR-4649-3p	0.013	0.45
hsa-miR-3656	0.097	1.744	hsa-miR-4655-5p	0.005	-1.58
hsa-miR-3928-5p	0.04	-0.085	hsa-miR-4695-3p	0.005	2.33
hsa-miR-3960	0.084	3.018	hsa-miR-4788	0.069	1.7
hsa-miR-4271	0.07	2.006	hsa-miR-483-3p	0.016	3.99
hsa-miR-4281	0.088	2.84	hsa-miR-6069	0.011	-0.07
hsa-miR-4512	0.065	-1.302	hsa-miR-6085	0.041	1.96
hsa-miR-451a	0.099	40.596	hsa-miR-6165	0.088	0.37
hsa-miR-4740-3p	0.047	2.488	hsa-miR-6511a-3p	0.014	0.33
hsa-miR-5739	0.097	1.622	hsa-miR-6743-5p	0.057	0.92
hsa-miR-5787	0.094	2.814	hsa-miR-6812-5p	0.032	-0.29
hsa-miR-6090	0.051	1.198	hsa-miR-6825-3p	0.024	-0.26
hsa-miR-6165	0.011	0.372	hsa-miR-8089	0.039	0.91
hsa-miR-6741-5p	0.018	1.083	hsa-miR-937-5p	0.1	0.95
hsa-miR-6749-5p	0.066	1.547			
hsa-miR-6803-5p	0.072	1.743			
hsa-miR-6825-3p	0.082	-0.257			
hsa-miR-6869-5p	0.038	0.769			
hsa-miR-7977	0.057	2.809			

3
4 **Note:** Lists of differentially expressed miRNAs in mothers of lean vs. adipose neonates; 24
5 miRNAs in the unadjusted analysis and 19 miRNAs in adjusted analysis (adjusted for
6 maternal glycemic status (GDM/NGT), maternal adiposity (lean if below median and adipose
7 if above median), and maternal vitamin B12 and folate status (inadequate if below median
8 and adequate if above median)) were found to be differentially expressed at p<0.1.
9

1 **Table 2B. Lists of differentially expressed ADsEV miRNAs in cord blood of adipose Vs lean**
2 **neonates**

Cord miRNA (unadjusted)			Cord miRNA (adjusted)		
miRNA	P-value	Fold change	miRNA	P-value	Fold change
hsa-miR-15a-5p	0.074	-0.912	has-let-7d-3p	0.091	9
hsa-miR-3162-3p	0.087	1.49	hsa-miR-1225-5p	0.094	22.84
hsa-miR-342-3p	0.049	-0.098	hsa-miR-1227-5p	0.02	1.43
hsa-miR-4433a-5p	0.088	1.768	hsa-miR-1249-3p	0.061	1.27
hsa-miR-483-5p	0.061	2.943	hsa-miR-1268a	0.077	2.52
			hsa-miR-181b-5p	0.031	0.71
			hsa-miR-204-5p	0.085	9.87
			hsa-miR-212-3p	0.094	-0.39
			hsa-miR-3162-3p	0.051	1.49
			hsa-miR-320c	0.066	-5.12
			hsa-miR-4433a-5p	0.02	1.77
			hsa-miR-4634	0.087	-0.83
			hsa-miR-4721	0.005	1.09
			hsa-miR-4741	0.064	-7.01
			hsa-miR-4788	0.069	-2.04
			hsa-miR-519e-3p	0.077	7.03
			hsa-miR-6089	0.078	4.37
			hsa-miR-6124	0.092	9.77
			hsa-miR-642b-3p	0.094	1.81
			hsa-miR-6716-3p	0.019	7.8
			hsa-miR-6815-3p	0.032	1.46
			hsa-miR-6865-3p	0.054	2.02
			hsa-miR-6866-3p	0.069	6.59
			hsa-miR-8071	0.009	-0.94
			hsa-miR-8089	0.037	0.29
			hsa-miR-92a-3p	0.06	-0.36

3
4 **Note:** Lists of differentially expressed miRNAs in cord blood of lean vs. adipose neonates; 5
5 miRNAs in the unadjusted analysis and 26 miRNAs in adjusted analysis (adjusted for
6 neonatal gender, maternal glycemic status (GDM/NGT), maternal adiposity (lean if below
7 median and adipose if above median), and maternal vitamin B12 and folate status
8 (inadequate if below median and adequate if above median)) were found to be differentially
9 expressed at p<0.1.

1 **Figure legends:**

2 **Figure 1. Differentially expressed miRNAs between lean Vs adipose groups in maternal**
3 **and cord blood samples.** Volcano plots of maternal (A, B) and cord blood (C, D) miRNAs.
4 Significantly upregulated are shown in blue and downregulated in red, non-significant in
5 green. A fold change cut off ± 1.25 and a p-value cut-off of 0.1 are shown. Adjustment
6 included maternal GDM, adiposity, vitamin B12 and folate status, and additionally for
7 neonatal gender in cord blood.

8

9 **Figure 2A. Differentially expressed ADsEV miRNAs highlighted in maternal unadjusted**
10 **analysis:** The bar diagram (A) shows the DE miRNAs and their fold change expression in the
11 mothers of adipose neonates (unadjusted analysis) compared to mothers of lean neonates.
12 Fold change values have been capped to ± 5 . The network plot (B) highlights functionally
13 enriched miRNAs from this analysis and their target genes. The bubble plot (C) reveals
14 different adipogenesis related pathways targeted by the functionally enriched miRNAs.

15

16 **Figure 2B. Differentially expressed ADsEV miRNAs highlighted in maternal adjusted**
17 **analysis:** The bar diagram (A) shows the DE miRNAs and their fold change expression in the
18 mothers of adipose neonates compared to mothers of lean neonates (adjusted analysis;
19 adjustments included maternal GDM, adiposity, vitamin B12 and folate status). Fold change
20 values have been capped to ± 5 . The network plot (B) highlights functionally enriched
21 miRNAs from this analysis and their target genes. The bubble plot (C) reveals different
22 adipogenesis related pathways targeted by the functionally enriched miRNAs.

23

24 **Figure 3A: Differentially expressed ADsEV miRNAs highlighted in cord blood unadjusted**
25 **analysis:** The bar diagram (A) shows the DE miRNAs and their fold change expression in the
26 cord blood of adipose neonates (unadjusted analysis) compared to lean neonates. Fold
27 change values have been capped to ± 5 . The network plot (B) highlights functionally
28 enriched miRNAs from this analysis and their target genes. The bubble plot (C) reveals
29 different adipogenesis-related pathways targeted by the functionally enriched miRNAs.

30

31 **Figure 3B: Differentially expressed ADsEV miRNAs highlighted in cord blood adjusted**
32 **analysis:** The bar diagram (A) shows the DE miRNAs and their fold change expression in the
33 cord blood of adipose neonates compared to lean neonates (adjusted analysis; adjustments
34 included maternal GDM, adiposity, vitamin B12 and folate status, and additionally for
35 neonatal gender in cord blood). Fold change values have been capped to ± 5 . The network
36 plot (B) highlights functionally enriched miRNAs from this analysis and their target genes.
37 The bubble plot (C) reveals different adipogenesis-related pathways targeted by the
38 functionally enriched miRNAs.

39

1 **Figure 4: Complex interplay of DE ADsEVs miRNAs from maternal and cord blood in**
2 **adipogenesis related pathways**

3 The Sankey diagram shows the DE miRNAs in maternal and cord blood of adipose neonates
4 and their targeted pathways related to adipogenesis. The diagram highlights that though the
5 differentially expressed miRNAs were different in maternal and cord blood, they targeted
6 similar adipogenesis-related pathways. The numbers represent the total number of targeted
7 genes.

8
9 **Figure 5: Comparison of differentially expressed miRNAs in the 3 analyses:** The Venn

10 diagram shows the number of differentially expressed miRNAs found common and exclusive
11 to following 3 independent comparisons: 1, Neonatal adiposity (Lean Vs Adipose), 2,
12 Maternal hyperglycemia during pregnancy (NGT Vs GDM), and 3. Maternal adiposity (Lean
13 vs. Adipose)

14
15 **Supplementary figure 1: STROBE flow diagram for the selection of participants**

16
17 **Supplementary figure 2: STROBE Flow diagram for miRNA analysis**

18
19 **Supplementary figure 3: Comparison of average z-score of miRNA expression profile in**

20 **maternal and cord blood samples between lean Vs adipose groups:** The boxplots highlight
21 that (A) the average z-score of all miRNA expression was lower in mothers of adipose
22 neonates (red color) as compared to mothers of lean neonates (green color) ($p=0.053$). This
23 pattern was not observed in the cord blood (B) of adipose and lean neonates ($p=0.645$). The
24 z-scores were calculated as per the formula:


25 $Z\text{-score} = \frac{\text{average (expression of miRNA in each sample - median expression of that miRNA)}}{\text{Std. dev(miRNA)}}$
26

27


Figure 1. Differentially expressed miRNAs between lean Vs adipose groups in maternal and cord blood samples.

Group ● Down ● NS ● Up


A Mother: Unadjusted



B Mother: Adjusted



C Cord blood: Unadjusted



D Cord blood: Adjusted






Figure 2A

A: Mother: Fold change



B: Network



C: Pathways






Figure 2B

A: Mother: Fold change



B: Network



C: Pathways






Figure 3A

A: Cord blood: Fold change



B: Network



C: Pathways




Figure 3B




Figure 4. Complex interplay of DE ADsEVs miRNAs from maternal and cord blood in adipogenesis related pathways




Figure 5. Comparison of differentially expressed miRNAs in the 3 analyses

Outcome	MOTHERS (unadjusted + adjusted)		
	Neonatal adiposity	Maternal GDM	Maternal adiposity
Differential expression miRNAs	39	106	127
Functionally enriched miRNAs	7	29	34
Adipogenesis related miRNAs	4	19	25

Outcome	CORD BLOOD (unadjusted +adjusted)		
	Neonatal adiposity	Maternal GDM	Maternal adiposity
Differentially expressed miRNAs	29	81	57
Functionally enriched miRNAs	10	23	23
Adipogenesis related miRNAs	9	17	16

